FABPulous is a pioneering healthcare company based in The Netherlands, established in 2008 as a spinoff from Maastricht University. The company secured its initial equity financing in December 2009 with key investors including Thuja Capital, Health Innovations, Limburg Ventures, and NV Industriebank LIOF. The firm's innovative technology allows for rapid diluted plasma preparation from a single drop of blood, offering significant advantages for point-of-care and home testing applications. Their cutting-edge disposable plasma preparation device is designed to seamlessly integrate with various IVD detection platforms, including lateral flow devices. FABPulous' first product currently in development is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), aimed at facilitating early diagnosis of acute myocardial infarction.
Founded in 2000, FABPulous operates in the Biotechnology and Health Care industries, with a notable Venture Round investment received on October 17, 2017 from the Health Innovation Fund. The company's focus on developing ultra-rapid diagnostics for primary care and emergency medicine showcases its commitment to advancing healthcare accessibility and effectiveness.
